HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US TELL FRIEND RSS
 
Welcome to FDAweb
Pay Per View
Search our 72,047 - story database FREE
 
Free Items
 Warning Letters
 FDA Notices
 FDA Calendar
 

 FDA Whistleblowers



    








 
 
<< Prev  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next >>
 
TXT No FDA Action Against Accused Researchers [459 Words] [ Price : $8.95]
FDA denies a Public Citizen petition calling for the disqualification of two researchers at Hennepin County Medical Center, Minneapolis, MN, who “repeatedly and deliberately violated agency regulations intended to protect human subjects.”
05/02/2022
 
 
TXT Regeneron Awarded Priority Review Voucher [84 Words] [ Price : $8.95]
Federal Register notice: FDA issues Regeneron Pharmaceuticals a priority review voucher under its material threat medical countermeasure product program.
05/02/2022
 
 
TXT FDA Clears Auris Health Robotic Surgery Device [158 Words] [ Price : $8.95]
FDA clears an Auris Health (Ethicon subsidiary) 510(k) for its Monarch surgery platform’s expansion to endourological procedures.
05/02/2022
 
 
TXT Marqibo Accelerated Approval Withdrawn [111 Words] [ Price : $8.95]
Federal Register notice: FDA withdraws the accelerated approval of Acrotech Biopharma’s NDA for Marqibo (vincristine sulfate liposome injection), indicated for treating certain adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
05/02/2022
 
 
TXT FDA Seeks ‘Quality Process Change’ in Toripalimab BLA [245 Words] [ Price : $8.95]
FDA issues a complete response letter to Shanghai Junshi Biosciences and Coherus BioSciences on their BLA for toripalimab in combination with gemcitabine and cisplatin in patients with advanced recurrent or metastatic nasopharyngeal carcinoma, requesting a “quality process change.”
05/02/2022
 
 
TXT IND Safety Reports eSubmission Guide [149 Words] [ Price : $8.95]
FDA posts a final guidance entitled Electronic Submission of IND Safety Reports Technical Conformance Guide.
05/02/2022
 
 
TXT CDRH Unveils Organizational Changes, New Offices [204 Words] [ Price : $8.95]
CDRH announces organizational changes that include new offices established within the Office of Product Evaluation and Quality.
05/02/2022
 
 
TXT FDA Hold on Vertex Cell Therapy for Diabetes [318 Words] [ Price : $8.95]
FDA places a clinical hold on a Vertex Pharmaceuticals Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for certain people with Type 1 diabetes.
05/02/2022
 
 
TXT Bakul Patel Leaving CDRH After 13 Years [243 Words] [ Price : $8.95]
After 13 years at the agency, CDRH Digital Health Center of Excellence director Bakul Patel announces he will be leaving the agency early this month to explore an undisclosed new chapter in his professional life.
05/02/2022
 
 
TXT Latest Federal Register Notices [3016 Words] [ Price : $8.95]
FDA Review posts the Federal Register notices for the week ending 4/29/2022.
05/01/2022
 
 
<< Prev  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21  Next >>
 

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com